Metastatic renal cell carcinoma (mRCC) is kidney cancer that has spread beyond the kidney to other parts of the body. About 15% of people with kidney cancer are diagnosed at this distant stage, and the five-year relative survival rate for these patients is 19.1%. While that number reflects real challenges, treatment has changed dramatically in recent years, with combination immunotherapy regimens improving outcomes for many patients.
How Kidney Cancer Spreads
Renal cell carcinoma starts in the lining of the small tubes inside the kidney that filter blood and produce urine. When it becomes metastatic, the cancer cells have broken away from the original tumor and traveled through the bloodstream or lymphatic system to establish new tumors elsewhere. The most common destinations are the lungs, bones, liver, lymph nodes, adrenal glands, and brain. Cancer cells also frequently invade the renal vein and the large vein that carries blood from the lower body back to the heart (the inferior vena cava).
At a molecular level, kidney cancer often involves a malfunctioning gene that normally acts as a brake on tumor growth. When that gene stops working, cells ramp up signals that promote new blood vessel formation and rapid cell division. Several overlapping growth pathways drive this process, which is why treatment typically requires drugs that block more than one of these pathways at once.
Clear Cell vs. Non-Clear Cell Subtypes
About 75% of all renal cell carcinomas are the “clear cell” subtype, named for how the cells look under a microscope. The remaining 25% are classified as non-clear cell, which includes several rarer forms like papillary, chromophobe, collecting duct, and medullary carcinoma. This distinction matters because nearly all the large clinical trials that established today’s standard treatments enrolled patients with clear cell disease. Only about one-third of patients with non-clear cell subtypes respond to the same immunotherapy drugs, based on smaller studies.
Two particularly aggressive non-clear cell forms, collecting duct and medullary carcinoma, behave more like bladder cancer than typical kidney cancer. These subtypes are generally treated with platinum-based chemotherapy rather than the targeted therapies used for clear cell disease.
Symptoms of Advanced Disease
Early-stage kidney cancer often causes no symptoms at all, which is why many cases are discovered incidentally during imaging for something else. As the disease progresses or spreads, symptoms become more noticeable. The most common include blood in the urine, a palpable lump in the abdomen, persistent pain in the side or flank, unexplained weight loss, loss of appetite, and anemia.
Metastatic kidney cancer can also trigger what are called paraneoplastic syndromes, where the tumor releases substances that affect other organ systems. These can cause high blood pressure, elevated calcium levels, or abnormal liver function tests, even when the liver itself doesn’t contain cancer. Bone pain may signal that the cancer has spread to the skeleton, while headaches or neurological changes can indicate brain involvement.
How It’s Diagnosed and Staged
CT scans and MRI are the primary imaging tools for staging kidney cancer. A contrast-enhanced CT or MRI of the abdomen and pelvis can reveal the size of the primary tumor, whether it has grown into surrounding fat or blood vessels, and whether nearby lymph nodes are enlarged. Chest imaging checks for lung metastases, and because the thoracolumbar spine and ribs (common sites of bone spread) are covered by chest and abdominal scans, a separate bone scan isn’t always necessary unless you have bone pain or blood tests suggesting skeletal involvement.
Kidney cancer is classified as Stage IV, the most advanced stage, when it has spread to distant organs (any tumor size, any lymph node status, confirmed distant metastasis) or when the primary tumor has grown through the outer membrane of the kidney into surrounding structures. Doctors also assign a risk category using a model that evaluates six factors: anemia, high calcium, high platelet count, high white blood cell count (specifically neutrophils), overall physical functioning, and how quickly the cancer progressed from diagnosis to requiring treatment. Based on how many of these factors are present, patients fall into favorable, intermediate, or poor risk groups, which guides treatment decisions and helps predict outcomes.
First-Line Treatment Options
Treatment for metastatic clear cell RCC has shifted substantially toward combination regimens that pair two types of drugs. The standard approach now involves either two immunotherapy drugs together or an immunotherapy drug combined with a targeted drug that blocks blood vessel growth (a tyrosine kinase inhibitor). Five combination regimens are currently recommended as first-line options, and the specific choice depends on your risk category and overall health.
These combinations work through complementary mechanisms. The immunotherapy component helps your immune system recognize and attack cancer cells by removing molecular “brakes” that tumors exploit to hide. The targeted therapy component cuts off the blood supply the tumor needs to grow. By hitting the cancer from two angles, these regimens produce better response rates and longer survival than either approach alone.
Which combination your oncologist recommends depends on factors like your risk classification, kidney function, and any other health conditions that might make certain side effects more problematic. For example, dual immunotherapy may be preferred for intermediate and poor risk patients, while immunotherapy plus a targeted drug may be used across all risk groups.
The Role of Surgery
Removing the cancerous kidney (cytoreductive nephrectomy) used to be a standard first step for nearly all patients with metastatic disease, but its role has narrowed considerably. Surgery is still recommended for symptom relief when the primary tumor causes significant bleeding, pain, high blood pressure, or other problems that are hard to manage otherwise.
It also remains a strong option for patients with oligometastatic disease, meaning the cancer has spread to only a few sites. In these cases, surgically removing the primary tumor along with the small number of metastases can sometimes achieve complete disease control, potentially delaying or even avoiding the need for systemic drug therapy. Patients with only one unfavorable risk factor are the best candidates for this approach. For patients with widespread metastases or multiple poor risk factors, starting with drug therapy first is generally the better strategy.
Newer Targeted Therapies
One of the more significant recent advances targets a protein called HIF-2α, which plays a central role in kidney cancer biology. When the tumor-suppressor gene that normally keeps this protein in check is lost (which happens in most clear cell kidney cancers), HIF-2α drives the production of signals that fuel blood vessel growth and tumor expansion.
Belzutifan is the first drug designed to block HIF-2α directly. It was initially approved in 2021 for patients with a hereditary condition called Von Hippel-Lindau disease, which causes kidney tumors. In December 2023, its approval expanded to include patients with sporadic (non-hereditary) metastatic RCC who had already received prior treatment. This represented a genuinely new mechanism of action, distinct from both immunotherapy and the older generation of targeted drugs. Several next-generation drugs targeting the same pathway are in development, including approaches that use RNA interference to silence the gene entirely rather than just blocking the protein.
What Survival Numbers Actually Mean
The 19.1% five-year survival rate for distant-stage kidney cancer comes from data collected between 2015 and 2021. That timeframe is important because many of today’s combination immunotherapy regimens were approved during or after that period. Patients starting treatment now may benefit from options that weren’t available to many people captured in those statistics.
Risk stratification also means that a single survival number doesn’t apply equally to everyone. Patients in the favorable risk group, with zero or one adverse factors, can have meaningfully longer survival than the overall average suggests. Conversely, those in the poor risk category, with four or more adverse factors, face a more difficult prognosis. Your oncologist can use these risk models to give you a more personalized picture of what to expect based on your specific situation.